论文部分内容阅读
目的探讨依达拉奉治疗急性脑出血的临床疗效及机制。方法总结依达拉奉治疗我院130例急性脑出血患者的疗效,并与同期130例对照组进行对照分析。结果依达拉奉治疗组在21天治疗结束时神经功能缺损评分及日常生活活动能力评分均较对照组有明显改善,差异有显著性(P<0.05)。且治疗组治疗过程中未见明显不良反应,化验检查无异常变化。结论依达拉奉在减轻脑出血患者脑水肿,改善神经细胞缺失,保护脑细胞方面很有帮助,是治疗脑出血安全、有效的药物。
Objective To investigate the clinical efficacy and mechanism of edaravone in the treatment of acute cerebral hemorrhage. Methods The therapeutic effect of edaravone in treating 130 patients with acute cerebral hemorrhage in our hospital was summarized and compared with 130 control subjects in the same period. Results Edaravone treatment group at the end of treatment at 21 days neurological deficit score and daily living activity scores were significantly improved compared with the control group, the difference was significant (P <0.05). No significant adverse reactions were found in the treatment group during the treatment, and no abnormal changes were found in the laboratory tests. Conclusion Edaravone is a safe and effective drug for the treatment of cerebral hemorrhage in brain edema alleviation in patients with cerebral edema, improvement of nerve cell loss and protection of brain cells.